Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, Wei Tu, Courtney H Coschi, Federica Grosso, Marie Florescu, Manlio Mencoboni, John R Goffin, Maria Pagano, Fortunato Ciardiello, Fabiana Letizia Cecere, Mark Vincent, Roberto Ferrara, David E Dawe, Desiree Hao, Christopher W Lee, Alessandro Morabito, Cesare Gridelli, Luigi Cavanna, Mussawar Iqbal, Normand Blais, Natasha B Leighl, Paul Wheatley-Price, Ming-Sound Tsao, Francesca Ugo, Hazem El-Osta, Piera Gargiulo, Pierre-Olivier Gaudreau, Dongsheng Tu, Joana Sederias, Pamela Brown-Walker, Francesco Perrone, Lesley Seymour, Scott A Laurie
Immune checkpoint inhibitors have activity in mesothelioma. IND.227 was a phase II trial (120 patients planned) comparing progression free survival (PFS) of standard platinum pemetrexed (CP) versus CP/pembrolizumab (CP/pembro) versus pembrolizumab (pembro) . Accrual to pembro arm was discontinued based on interim analysis (IA - 16 week disease control rate (DCR)). CP/pembro was tolerable, with PFS similar between arms and median survival (OS) and overall response rate (RR) higher than CP alone (19.8 months [95% CI 8...
February 23, 2023: Journal of Thoracic Oncology